Data from a Phase I/II Study Presented at the 32nd San Antonio Breast …
Posted by: DrugsNews on: 12 Dec, 2009
Data from a Phase I/II Study Presented at the 32nd San Antonio Breast …
Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.
Read more about Data from a Phase I/II Study Presented at the 32nd San Antonio Breast …
Get pricing and discount on generic medicines for Diabetes from www.roxpharmacy.com
| Indian Pharmacy! Looking for Generic Medications? Quality Drugs at affordable prices! Reliable Indian Pharmacy www.IndianPharmacy.org |
#1 Canadian Pharmacy Online! The Lowest Prices from Canadian Drugstore! Various payments, secure shopping, worldwide shipping! www.CanadianPharmacyLtd.org |
What are the Drugs-Review websites?
The Drugs-Review websites are NOT but will be your number one stop for all the latest news, comment and pharmaceutical industry information.
Related posts:
- Data from a Phase I/II Study Presented at the 32nd San Antonio Breast …
- Data from a Phase I/II Study Presented at the 32nd San Antonio Breast Cancer Symposium Suggest that INCB7839 in Combination with Trastuzumab May Improve Clinical Response Rates in HER2 Positive Patients with Advanced Metastatic Disease
- Institut Paoli Calmettes and Ipsogen Presented a New Study Supporting the Pivotal Role of Tumor Grade in Chemotherapy Prescription at the 32nd Annual San Antonio Breast Cancer Symposium
